Preliminary Report of the Academic CAR-T (ISIKOK-19) Cell Clinical Trial in Turkey: Characterization of Product and Outcomes of Clinical Application

Ebru Erdoğan Koray YalÇin Cansu HemşinlioğluAslıhan SezginUtku Seyis Derya Dilek Kançağı Cihan TaŞtan Bulut Yurtsever Raife Dilek TuranDidem ÇakırsoySelen AbanuzGözde Sır KarakuşMuhammer ElekHüseyin Saffet BekozAli İhsan GemiciDeniz SargınMutlu Arat Burhan FerhanoğluEbru PekgüçSerdar Örnek Deram Büyüktaş Nur Birgen Siret Ratip Ercüment Ovalı

Published in: Turkish journal of haematology : official journal of Turkish Society of Haematology (2022)

Production efficacy and fulfillment of the criteria of quality control were satisfactory for academic production. Response rates and toxicity profiles were also acceptable for this heavily pretreated/refractory patient group. ISIKOK-19 cells appear to be a safe, economical, and efficient treatment option for CD19+ tumors. However, the findings of this study need to be supported by the currently ongoing ISIKOK-19 clinical trial.

Keyphrases